Our pipeline of new molecular entities is well-positioned to encompass multiple clinical-stage programs in the coming years and reflects our focus and commitment to bring medicines for treating medically-complex and serious conditions to patients with a high unmet medical need, notably in oncology and autoimmune diseases.

Synthon Biopharmaceuticals pipeline 2019
[vic-]trastuzumab duocarmazine (SYD985)

In 2014, we brought our most advanced ADC candidate SYD985 − or [vic-]trastuzumab duocarmazine as its official INN now is − to the clinic for a two-part first-in-human Phase I study.

In November 2017, Synthon Biopharmaceuticals initiated the pivotal Phase III TULIP® trial, a multi-center, open-label, randomized clinical trial comparing the efficacy and safety of [vic-]trastuzumab duocarmazine to physician's choice treatment in patients with HER2-positive unresectable locally advanced or metastatic breast cancer. 

read more
     Share this page